GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (NYSE:ZTS) » Definitions » Net Income From Continuing Operations
中文

Zoetis (Zoetis) Net Income From Continuing Operations : $2,340 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Zoetis Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zoetis's net income from continuing operations for the three months ended in Dec. 2023 was $523 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $2,340 Mil.


Zoetis Net Income From Continuing Operations Historical Data

The historical data trend for Zoetis's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Net Income From Continuing Operations Chart

Zoetis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,500.00 1,636.00 2,034.00 2,111.00 2,340.00

Zoetis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 460.00 551.00 670.00 596.00 523.00

Zoetis Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,340 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zoetis (Zoetis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (NYSE:ZTS) » Definitions » Net Income From Continuing Operations
Address
10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Executives
Roxanne Lagano officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Kristin C Peck officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Heidi C. Chen officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Robert J Polzer officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Soria Ester Banque officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Rimma Driscoll officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Jamie Brannan officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Vanessa Broadhurst director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Willie M Reed director C/O ZOETIS, 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Nicholas Ashton officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Roman Trawicki officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Glenn David officer: SVP and Acting CFO C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Astorga Jeannette Ferran officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Catherine A. Knupp officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07940
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005

Zoetis (Zoetis) Headlines

From GuruFocus

Q3 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2021 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc at Jefferies Pet Summit (Virtual) Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc Investor Day Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024